Endometrial cancer in postmenopausal women using estradiol-progestin therapy

Obstetrics and Gynecology

Volumn 114, Issue 6, 2009, Pages 1197-1204

  Ylikorkala, Olavi ^a   Jaakkola, Susanna ^b   Lyytinen, Heli ^b   Pukkala, Eero ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; GESTAGEN; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE ACETATE; TRIMEGESTONE; ESTROGEN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLEAR CELL CARCINOMA; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; FINLAND; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; AGED; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECT; ENDOMETRIUM TUMOR; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG THERAPY, COMBINATION; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGENS; FEMALE; FINLAND; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RETROSPECTIVE STUDIES;

EID: 73349103184     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181bea950     Document Type: Article

References (41)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366:491-505.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-1543
4. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004;35:649-662
5. Brown L. Pathology of uterine malignancies. Clin Oncol (R Coll Radiol) 2008;20:433-447
6. Bjorge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 2007;120:378-383
7. Weiss JM, Saltzman BS, Doherty JA, Voigt LF, Chen C, Beresford SA, et al. Risk factors for the incidence of endome-trial cancer according to the aggressiveness of disease. Am J Epidemiol 2006;164:56-62.
8. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008;17:73-79
9. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: Endometrial hyperplasia and irregular bleeding. The Cochrane Database of Systematic Reviews, Issue 3. Art No.: CD000402.
10. Stanczyk FZ. Percutaneus administration of progesterone: blood levels and endometrial protection. Menopause 2005;2: 232-237
11. Stanczyk FZ. All progestins are not created equal. Steroids 2003;68:879-890
12. Davis SR, Dinatale I, Rivera-Woll L, Davison S. Postmeno-pausal hormone therapy: From monkey glands to transdermal patches. J Endocrinol 2005;185:207-222
13. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 2007;91:1-528.
14. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005;6:552-553 (Pubitemid 41051931)
15. Keskimaki I, Aro S, Teperi J. Regional variation in surgical procedure rates in Finland. Scand J Soc Med 1994;22:132-138
16. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-369
17. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven Publishers; 1998. p 264.
18. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65-73.
19. Pukkala E, Weiderpass E. Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971-1995). Int J Cancer 1999;81:56-61.
20. Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeco-nomic differences in the use of menopausal and postmeno-pausal hormone therapy in Finland. Maturitas 1999;32:141-145
21. Luoto R, Raitanen J, Pukkala E, Anttila A. Effect of hysterectomy on incidence trends of endometrial and cervical cancer in Finland 1953-2010. Br J Cancer 2004;90:1756-1759
22. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116
23. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461
24. Weiderpass E, Adami HO, Baron JA, Magnusson C, Berg-strom R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-1137 (Pubitemid 29330551)
25. Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomar-kers Prev 2005;14:1724-1731
26. Doherty JA, Cushing-Haugen KL, Saltzman BS, Voigt LF, Hill DA, Beresford SA, et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007;197:139.e1-7
27. The writing group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmeno-pausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;275:370-375
28. Reed SD, Voigt LF, Beresford SA, Hill DA, Doherty JA, Weiss NS. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 2004;191:1146-1151
29. Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet 2005;365:1543-1551
30. Lacey JV Jr, Leitzmann MF, Chang SC, Mouw T, Hollenbeck AR, Schatzkin A, et al. Endometrial cancer and menopausal hormone therapy in the national institutes of health-AARP diet and health study cohort. Cancer 2007;109:1303-1311 (Pubitemid 46466557)
31. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Baillieres Best Pract Res Clin Endocrinol Metab 2003;17:139-147
32. Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian long cycle study group. Maturitas 1999;32: 161-170
33. Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control 2001;12:111-115
34. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007;56:231-248
35. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The women's health initiative randomized trial. JAMA 2003;290: 1739-1748 (Pubitemid 37430624)
36. Wells M, Sturdee DW, Barlow DH, Ulrich LG, O'Brien K, Campbell MJ, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: Follow up study. BMJ 2002;325:239-243
37. L'Hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer posmeno-pausal HRT? A review. Maturitas 2008;60:185-201.
38. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111
39. Weiss JM, Saltzman BS, Doherty JA, Voigt LF, Chen C, Beresford SA, et al. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol 2006;164:56-62.
40. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227-242
41. Acharya S, Hensley ML, Montag AC, Fleming GF. Rare uterine cancers. Lancet Oncol 2005;6:961-971